MedMen Enterprises Inc. (CSE: MMEN)(OTCQX: MMNFF), has announced this morning that the company has engaged Canaccord Genuity Corp. at act as lead underwriter and sole book-runner to sell 17,648,000 units at a price of $6.80 per units. The total gross proceeds of the capital raise is expected to be gross proceeds of C$120,006,400.
The units also are accompanied by options to purchase an additional 2,647,200 of the shares issued at the original price. If all of the options are exercised in full then the company expects to raise an additional $18,000,960.
MedMen has recently taken their company public on the Canadian Securities Exchange in order to be capable of raising working capital to expand their operations in the United States and Canada. They sell a variety of different cannabinoid-based products in their store locations to both medicinal patients and recreational users.
Mainly, MedMen have locations located on the West and East Coasts of the United States. The company has recently begun construction of a cultivation and manufacturing facility in Desert Hills, California. Their new facility will contain 26,000 sq. ft. of Dutch-style greenhouses that will be 100% automated. Their expectation is to product 10,000 pounds of dried cannabis annually.
You may be interested
Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio OregonEditor - November 27, 2018
Vancouver, BC -- (November 27, 2018) -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) and its joint venture…
Wayland Group Enters UK Cannabis Market with Theros Pharma AcquisitionEditor - November 26, 2018
Wayland Group (CSE:WAYL) (OTCQB:MRRCF) has announced this morning that their company has entered into an agreement to acquire 51% of UK company Theros Pharma Ltd. The Wayland Group…
GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical TrialsEditor - November 26, 2018
GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®.…